Aclarion price to sales ratio ACON

Market value divided by revenue over the last twelve months, since 2023.

Today, Oct 23, 2026: 66.4×
4-year median: 52.6×
Against its 4-year history: 58th; percentile: 0 is its lowest day, 100 its highest
4-year range: 0.2× to 163×
Peer median: 1.4×

Aclarion's price to sales ratio is 66.4× as of Oct 23, 2026.

That is above its 4-year median of 52.6×, close to the middle of its last 4 years.

Over that time it ranged from 0.2× in May 2024 to 163× in Jun 2023.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	66.4×	25.3×	113×
2025	53.6×	0.3×	114×
2024	3.0×	0.2×	20.5×
2023	20.9×	20.9×	163×

Against its peers

Companies in Healthcare nearest Aclarion's size, closest first, today.

Company	Price to sales ratio
ACONAclarion	66.4×
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
VIPVulcan Infrastructure & Power	0.4×
MXCMexco Energy	3.0×
CKXCKX Lands	31.0×
MSGMMotorsport Games	1.5×
ATCHAtlasClear	1.2×
Peer median	1.4×

Where Aclarion ranks

#61of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Aclarion

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.